Check th to Sectio obligation Instruction 1(b).

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

s box if no longer subject	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
n 16. Form 4 or Form 5	
is may continue. See	

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response	e: 0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Spellman David A						2. Issuer Name and Ticker or Trading Symbol Akebia Therapeutics, Inc. [ AKBA ]								(Ched	k all app	,	ng Pe	rson(s) to Is  10% O  Other (	wner
		RAPEUTICS, IN	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/16/2021								X	belov			below)		
245 FIRST STREET  (Street)  CAMBRIDGE MA 02142  (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)							Line) X	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benef	iciall	y Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day				Execution Date,				es Acquired (A Of (D) (Instr. 3,		4 and Securi Benefi		ties cially Following	Forn (D) c	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A) (D)	or Pi	rice	Transa	action(s) 3 and 4)			(5 4)	
Common Stock 03/16/2				2021		A		7,592(1)	7,592 <sup>(1)</sup> A		\$0.00	0 77,592			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rative   Conversion   Date   Execution Date,   rity   or Exercise   (Month/Day/Year)   if any			Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Insi 3 and 4)		De Se (Ir	Price of Privative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Exercis	able	Date	Title	Share	s					

## **Explanation of Responses:**

1. As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020. Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date.

## Remarks:

/s/ Andrea J. Paul, attorney-in-03/18/2021 fact for David A. Spellman

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.